Rocket Pharmaceuticals continues to advance its multi-platform genetic therapy pipeline focusing on severe rare disorders, navigating ongoing regulatory feedback loops, clinical updates, and strategic operational management. Recent updates include consensus earnings revisions and routine insider transactions by executive officers.